A5052401364- Pharmacogenetics and Drug Metabolism
- Drug Transport and Resistance Mechanisms
- Drug-Induced Hepatotoxicity and Protection
- Biochemical and Molecular Research
- Colorectal Cancer Treatments and Studies
- Computational Drug Discovery Methods
- Pancreatic and Hepatic Oncology Research
- Malaria Research and Control
- Medicinal Plants and Neuroprotection
- Neurological Disease Mechanisms and Treatments
- Tryptophan and brain disorders
- HIV/AIDS drug development and treatment
- Peroxisome Proliferator-Activated Receptors
- Regulation of Appetite and Obesity
- Innovative Microfluidic and Catalytic Techniques Innovation
- Pharmaceutical studies and practices
- Cancer, Hypoxia, and Metabolism
- Eicosanoids and Hypertension Pharmacology
- Neuroinflammation and Neurodegeneration Mechanisms
- Bioactive Compounds in Plants
Tohoku University
2017-2024
Meijo University
2020-2022
Tohoku University Hospital
2020-2022
Tohoku Medical Megabank Organization
2020-2022
Center for Innovation
2022
Hiroshima City University
2022
CYP3A4 is among the most abundant liver and intestinal drug-metabolizing cytochrome P450 enzymes, contributing to metabolism of more than 30% clinically used drugs. Therefore, interindividual variability in activity a frequent cause reduced drug efficacy adverse effects. In this study, we characterized wild-type 40 variants, including 11 new detected 4773 Japanese individuals by assessing enzymatic activities for two representative substrates (midazolam testosterone). The carbon...
Abstract The evaluation of Cytochrome P450 (CYP) enzymatic activity is essential to estimate drug pharmacokinetics. Numerous CYP allelic variants have been identified; the functional characterisation these required for their application in precision medicine. Results from heterologous expression systems using mammalian cells can be integrated vivo studies; however, other such as E. coli , bacteria, yeast, and baculoviruses are generally used owing difficulty expressing high levels cells....
Cytochrome P450 3A4 (CYP3A4) enzyme is involved in the metabolism of about 30 % clinically used drugs, including antimalarials artemether and lumefantrine. CYP3A4 polymorphisms yield enzymatic variants that contribute to inter-individual variation drug metabolism. Here, we examined populations from malaria-endemic islands Lake Victoria, Kenya, Vanuatu, expand on limited data sets. We archived dried blood spots collected 142 Kenyan 263 ni-Vanuatu adults during cross-sectional malaria surveys...
Cytochrome P450 2C9 (CYP2C9) is an important drug-metabolizing enzyme that contributes to the metabolism of approximately 15% clinically used drugs, including warfarin, which known for its narrow therapeutic window. Interindividual differences in CYP2C9 enzymatic activity caused by genetic polymorphisms lead inconsistent treatment responses patients. Thus, this study, we characterized functional wild-type (CYP2C9.1), CYP2C9.2, CYP2C9.3, and 12 rare novel variants identified 4773 Japanese...
Cytochrome P450 1A2 (CYP1A2), which accounts for approximately 13% of the total hepatic cytochrome content, catalyzes metabolic reactions 9% frequently used drugs, including theophylline and olanzapine. Substantial inter-individual differences in enzymatic activity have been observed among patients, could be caused by genetic polymorphisms. Therefore, we functionally characterized 21 novel CYP1A2 variants identified 4773 Japanese individuals determining kinetic parameters phenacetin
The drug 5-fluorouracil (5-FU) is the first-choice chemotherapeutic agent against advanced-stage cancers. However, 10% to 30% of treated patients experience grade 3 4 toxicity. deficiency dihydropyrimidinase (DHPase), which catalyzes second step 5-FU degradation pathway, correlated with risk developing Thus, genetic polymorphisms within <i>DPYS,</i> DHPase-encoding gene, could potentially serve as predictors severe 5-FU-related We identified 12 novel <i>DPYS</i> variants in 3554 Japanese...